Harlan Robins - Adaptive Biotechnologies Co-Founder, Chief Scientific Officer
| ADPT Stock | USD 5.73 0.05 0.88% |
Founder
Dr. Harlan Robins is a CoFounder, Chief Scientific Officerof the Company.Dr. Robins leads our scientific research and development teams. He is also currently an Associate Faculty Member of the Fred Hutchinson Cancer Research Center . Dr. Robins background in science is remarkable. He obtained his bachelors degree at Harvard University as a physics major with a concentration in mathematics. He then obtained his Masters and Ph.D. in theoretical physics from the University of California Berkeley Science in Israel. Interested in the mathematics behind genetics and observing the potential utility of highlevel mathematics to study problems in the biological sciences, Dr. Robins took another postdoctoral appointment at the Institute for Advance Study in Princeton to study under the famed biologist Dr. Arnold Levine. Working with Dr. Levine, Dr. Robins concentrated on developing bioinformatic algorithms for micro RNA targets and bacterial genome analysis, a precursor to his current faculty appointment at the Fred Hutchinson Cancer Research Center in the Computational Biology Group, Public Health Sciences and Human Biology Divisions. In 2009, Dr. Robins was the recipient of the Ellison Award from the Ellison Medical Foundation New Scholars Program to support new investigators of outstanding promise in the basic biological sciences
| Age | 51 |
| Professional Marks | Ph.D |
| Address | 1165 Eastlake Avenue East, Seattle, WA, United States, 98109 |
| Phone | 206 659 0067 |
| Web | https://www.adaptivebiotech.com |
Adaptive Biotechnologies Management Efficiency
The company has return on total asset (ROA) of (0.1637) % which means that it has lost $0.1637 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6676) %, meaning that it created substantial loss on money invested by shareholders. Adaptive Biotechnologies' management efficiency ratios could be used to measure how well Adaptive Biotechnologies manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.44 in 2024. Return On Capital Employed is likely to drop to -0.42 in 2024. At this time, Adaptive Biotechnologies' Liabilities And Stockholders Equity is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 276.3 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 84.7 M in 2024.Similar Executives
| Found 2 records | FOUNDER Age | ||
| Burt MD | Verve Therapeutics | 72 | |
| Pascal Deschatelets | Apellis Pharmaceuticals | 54 | |
Management Performance
| Return On Equity | -0.67 | ||||
| Return On Asset | -0.16 |
Adaptive Biotechnologies Leadership Team
Elected by the shareholders, the Adaptive Biotechnologies' board of directors comprises two types of representatives: Adaptive Biotechnologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Adaptive. The board's role is to monitor Adaptive Biotechnologies' management team and ensure that shareholders' interests are well served. Adaptive Biotechnologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Adaptive Biotechnologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Yi Zhou, Chief Officer | ||
| Tycho Peterson, Chief Officer | ||
| Stacy JD, General VP | ||
| Harlan Robins, Co-Founder, Chief Scientific Officer | ||
| Kyle Piskel, Principal Officer | ||
| Susan Bobulsky, Chief MRD | ||
| Stacy Taylor, General VP | ||
| Mark Adams, Chief Officer | ||
| Julie Rubinstein, President COO | ||
| Francis Lo, Chief Officer | ||
| Sharon Benzeno, Chief Medicine | ||
| Karina Calzadilla, Vice Relations | ||
| Chad MBA, CEO CoFounder | ||
| Nitin Sood, Chief MRD | ||
| MBA MBA, CEO CoFounder | ||
| Mary Lancelotta, Senior BioPharma | ||
| Christopher Carlson, Founder |
Adaptive Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Adaptive Biotechnologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.67 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (1.10) % | ||||
| Operating Margin | (0.70) % | ||||
| Current Valuation | 694.13 M | ||||
| Shares Outstanding | 147.58 M | ||||
| Shares Owned By Insiders | 1.92 % | ||||
| Shares Owned By Institutions | 93.97 % | ||||
| Number Of Shares Shorted | 8.2 M | ||||
| Price To Earning | 0.25 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Adaptive Stock Analysis
When running Adaptive Biotechnologies' price analysis, check to measure Adaptive Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptive Biotechnologies is operating at the current time. Most of Adaptive Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adaptive Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptive Biotechnologies' price. Additionally, you may evaluate how the addition of Adaptive Biotechnologies to your portfolios can decrease your overall portfolio volatility.